JOHNSON & JOHNSON - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 13, 2026, for the 2025 Q4 period, JOHNSON & JOHNSON held in its portfolio 17 assets valued at $554,625,589 (i.e. $554.63M).

The most valuable assets in the portfolio included: Protagonist Therapeutics Inc. ($213.91M), Nanobiotix S.A. ($130.02M), and Rapport Therapeutics, Inc. ($54.14M).

The chart below shows the top 10 valuable assets, and the table below shows the top 17 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in JOHNSON & JOHNSON Portfolio

Protagonist Therapeutics Inc.

Nanobiotix S.A.

Rapport Therapeutics, Inc.

MeiraGTx Holdings plc

CVRx, Inc.

Contineum Therapeutics Inc.

Legend Biotech Corporation

Xencor, Inc.

Procept BioRobotics Corporation

Fate Therapeutics, Inc.

JOHNSON & JOHNSON - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
Protagonist Therapeutics Inc.	2449183	213911643	COM
Nanobiotix S.A.	5623816	130022626	SPONSORED ADS
Rapport Therapeutics, Inc.	1784517	54142246	COM
MeiraGTx Holdings plc	6641064	52796459	COM
CVRx, Inc.	4024861	28576513	COM
Contineum Therapeutics Inc.	1979173	22621947	CL A
Legend Biotech Corporation	814586	17709100	SPONSORED ADS
Xencor, Inc.	748062	11452829	COM
Procept BioRobotics Corporation	357939	11260761	COM
Fate Therapeutics, Inc.	3379064	3320268	COM
Neumora Therapeutics, Inc.	1849445	3310507	COM
Rallybio Corporation	3636363	2494909	COM
Lyell Immunopharma, Inc.	41165	1267059	COM NEW
Vor Biopharma, Inc.	53732	702815	COM NEW
Nano-X Imaging Ltd.	158852	444786	ORD SHS
Standard BioTools, Inc.	311967	399318	COM
Adicet Bio, Inc.	22779	191803	COM NEW